Extracellular Vesicles and Cancer Multidrug Resistance: Undesirable Intercellular Messengers?
Life · 27.07.2023 · 13 (8) · 1633
DOI: 10.3390/life13081633 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life, online erschienen am 27.07.2023. Verfasst von María Bucci-Muñoz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Ciencias Bioquímicas y Farmacéuticas (UNR), Instituto de Fisiología Experimental (CONICET), Rosario 2000, Argentina. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Promoción Científico Tecnologica, European Union's Horizon 2020 research and innovation programme, German Research Foundation (DFG).
Abstract (Originalsprache)
Cancer multidrug resistance (MDR) is one of the main mechanisms contributing to therapy failure and mortality. Overexpression of drug transporters of the ABC family (ATP-binding cassette) is a major cause of MDR. Extracellular vesicles (EVs) are nanoparticles released by most cells of the organism involved in cell–cell communication. Their cargo mainly comprises, proteins, nucleic acids, and lipids, which are transferred from a donor cell to a target cell and lead to phenotypical changes. In this article, we review the scientific evidence addressing the regulation of ABC transporters by EV-mediated cell–cell communication. MDR transfer from drug-resistant to drug-sensitive cells has been identified in several tumor entities. This was attributed, in some cases, to the direct shuttle of transporter molecules or its coding mRNA between cells. Also, EV-mediated transport of regulatory proteins (e.g., transcription factors) and noncoding RNAs have been indicated to induce MDR. Conversely, the transfer of a drug-sensitive phenotype via EVs has also been reported. Additionally, interactions between non-tumor cells and the tumor cells with an impact on MDR are presented. Finally, we highlight uninvestigated aspects and possible approaches to exploiting this knowledge toward the identification of druggable processes and molecules and, ultimately, the development of novel therapeutic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Facultad de Ciencias Bioquímicas y Farmacéuticas (UNR), Instituto de Fisiología Experimental (CONICET), Rosario 2000, Argentina.
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
ORCID-Profile: María Bucci-Muñoz, Juan Pablo Rigalli
Förderung
- Agencia Nacional de Promoción Científico Tecnologica
- European Union's Horizon 2020 research and innovation programme
- German Research Foundation (DFG)
- CONICET
- European Union’s Horizon 2020 research and innovation program
- ANPCyT
Zitieren
APA
Bucci-Muñoz, M., Gola, A. M., Rigalli, J. P., Ceballos, M. P., & Ruiz, M. L. (2023). Extracellular Vesicles and Cancer Multidrug Resistance: Undesirable Intercellular Messengers?. Life, 13(8), 1633. https://doi.org/10.3390/life13081633
Vancouver
Bucci-Muñoz M, Gola AM, Rigalli JP, Ceballos MP, Ruiz ML. Extracellular Vesicles and Cancer Multidrug Resistance: Undesirable Intercellular Messengers?. Life. 2023;13(8):1633. doi:10.3390/life13081633
BibTeX
@article{BucciMuoz2023,
author = {Bucci-Muñoz, María and Gola, Aldana Magalí and Rigalli, Juan Pablo and Ceballos, María Paula and Ruiz, María Laura},
title = {Extracellular Vesicles and Cancer Multidrug Resistance: Undesirable Intercellular Messengers?},
journal = {Life},
year = {2023},
volume = {13},
number = {8},
pages = {1633},
doi = {10.3390/life13081633}
}
EUVIMED